LGD-3303 (liquid)

What is LGD-3303?

The company Ligand Pharmaceuticals originally developed the lead compound LGD-4033. In 2007, they synthesized a derivative called 9-Chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinoline-7(6H)-one, better known as LGD-3303. This SARM, which is commercially available, is an orally administered, non-steroidal compound. Early studies with animal models have shown that it can increase bone mineral density (BMD) and muscle mass. Due to its high bioavailability and reported effectiveness, LGD-3303 is currently being investigated for its ability to prevent muscle wasting and osteoporosis.

Research results

• Increases muscle mass without negatively affecting prostate weight in male Sprague-Dawley rats that have undergone orchiectomy.
• Increases both the bone mineral content (BMC) and the BMD in female Sprague-Dawley rats after ovariectomy.

Methodology

Experiment 1: Male rats

Male Sprague-Dawley rats aged 7–8 weeks, each weighing approximately 200 grams, were purchased from Harlan for experimental testing. After a recovery period of 14 days, the rats were treated with varying doses of LGD-3303 or testosterone propionate. After two weeks, the rats were euthanized to allow for further analyses.

Experiment 2: Female rats

Female Sprague-Dawley rats, approximately 3 months old and weighing 175–200 grams, were also purchased from Harlan. After a recovery period of 7 weeks, the rats were assigned to different treatment groups and treated for 12 weeks.

Discussion

• The study showed that both LGD-3303 and testosterone propionate could increase anabolic activity in male rats that had undergone orchidectomy. However, unlike testosterone, LGD-3303 increased muscle weight without a significant increase in prostate weight.
• In female rats, treatment with LGD-3303 led to a significant increase in both bone mineral content and bone mineral density. This suggests that LGD-3303 has an effective anabolic activity on bone.

In the biomechanical tests, it was confirmed that all three treatment groups showed improvements, but the combination treatment was the most successful, although not significantly more than the treatment with only LGD-3303.

🧪 Contents

The bottle contains a solution of 10 mg/ml.
There is a glass pipette in the bottle with a scale of 0.2 ml to 1 ml, which allows you to dose easily and accurately.

📄 Disclaimer

This material is sold exclusively for use in laboratory research. Sales conditions apply. Not for human consumption, nor for medical, veterinary, or household use. Familiarize yourself with our DISCLAIMER before ordering.